In This Article:
NEW YORK, NY / ACCESSWIRE / May 5, 2018 / Pomerantz LLP announces that a class action lawsuit has been filed against Solid Biosciences Inc. (''Solid Biosciences'' or the ''Company'') (SLDB) and certain of its officers. The class action, filed in United States District Court, District of Massachusetts, and docketed under index number 18-cv-10639, is on behalf of a class consisting of investors who purchased or otherwise acquired Solid's securities: (1) pursuant and/or traceable to Solid's false and misleading Registration Statement and Prospectus, issued in connection with the Company's initial public offering on or about January 25, 2018 (the ''IPO'' or the ''Offering''); and/or (2) on the open market between January 25, 2018 and March 14, 2018, both dates inclusive (the ''Class Period''), seeking to recover damages caused by defendants' violations of the Securities Act of 1933 (the ''Securities Act'') and the Securities Exchange Act of 1934 (the ''Exchange Act'').
If you are a shareholder who purchased Solid securities between January 25, 2018, and March 14, 2018, both dates inclusive, you have until May 29, 2018, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
[Click here to join this class action]
Solid Biosciences is a biotechnology company that purportedly develops therapies and devices for patients with duchenne muscular dystrophy (DMD). The Company's lead product candidate, SGT-001, is a gene transfer under development to restore functional dystrophin protein expression in patients' muscles. The Company's therapy uses adeno-associated virus (AAV) to deliver the transgene into the patient.
The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Solid Biosciences' lead drug candidate SGT-001 had a high likelihood of causing adverse events in patients; (ii) Solid Biosciences misled investors regarding the toxicity of SGT-001; and (iii) as a result of the foregoing, Solid Biosciences' public statements were materially false and misleading at all relevant times.